TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03170960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
Study: NCT00719511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purified allergen dose 1 integrated in a Patch system
Description: Epicutaneous application of a patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purified allergen dose 2 integrated in a Patch system
Description: Epicutaneous application of a patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purified allergen dose 3 integrated in a Patch system
Description: Epicutaneous application of a patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purified allergen integrated in a Patch system
Description: Epicutaneous application of a patch
Study: NCT04102761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intradiscal PRP & BMC Injections
Description: The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
Study: NCT01393600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 12.5 mg powder in bottle once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 50 mg powder in bottle once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution containing no active substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution containing no active substance
Study: NCT04996186

Intervention type: OTHER
Intervention: Clinical interviews
Description: Semi-qualitative interviews and questionnaire STAR-Q
Study: NCT02391259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 557
Description: AMG 557 is for the treatment of sybjects with systemic lupus erythematosus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains no active drug
Study: NCT03170960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
Study: NCT03048396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus transplantation
Study: NCT05601310

Intervention type: DEVICE
Intervention: liquid chromatography-mass spectrometry (LC/MS) analysis
Description: To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.

Intervention type: DEVICE
Intervention: liquid chromatography-mass spectrometry (LC/MS) analysis
Description: To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.

Intervention type: DEVICE
Intervention: liquid chromatography-mass spectrometry (LC/MS) analysis
Description: To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.
Study: NCT02945527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: As described above
Study: NCT03170960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
Study: NCT04102761

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intradiscal PRP & BMC Injections
Description: The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
Study: NCT02260804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P10
Description: 375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan
Description: 375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
Study: NCT01728870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unique Diet+Partial Enteral Nutrition
Description: Modulen - liquid dietary formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exclusive Enteral Nutrition (Modulen)
Study: NCT01509651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
Study: NCT03051906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab given intravenously at 1500 mg every 4 weeks; first two cycles concurrent with RT + cetuximab, 6 cycles after the end of RT as adjuvant treatment; treatment will be continued for a maximum of 8 months (concurrent phase included).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab given intravenously weekly at 400mg/m2 loading dose 1 week before RT start, then 250 mg/m2 weekly thereafter.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Description: A total dose of 69.9 Gy will be given with 2.12 Gy dose per fraction, delivered in 33 fractions over 7 weeks.
Study: NCT03222869

Intervention type: DIAGNOSTIC_TEST
Intervention: Measure Airway Resistance Across Stenosis
Description: Measure pressure and air flow Across Stenosis
Study: NCT04606225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: administration of losartan (50 mg) (oral) Cozaar Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: administration of placebo (oral)
Study: NCT01621763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel Tablets 300 mg
Study: NCT03170960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
Study: NCT02945527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: As described above
Study: NCT01621763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel Tablets 300 mg
Study: NCT02701374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-700
Study: NCT03926351

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Soft gelatine capsule containing 1000 mg olive oil, refined.
Study: NCT02588963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education session
Description: It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
Study: NCT02701374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-700

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00944762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecosystem Focused Therapy (EFT)
Description: 12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education in stroke and depression
Description: Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
Study: NCT02718365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wedge resection
Description: A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Segmentectomy
Description: A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
Study: NCT02588963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal clearance Protocol
Description: Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal clearance Protocol
Description: Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
Study: NCT04293211

Intervention type: OTHER
Intervention: Simulation
Description: To measure the efficacy of adding a high-fidelity simulation versus low fidelity simulation to the current B-Con Course. This will be assessed by evaluation of applying tourniquets properly and packing traumatic wounds as well as retention of these skills over a period of time amongst school teachers and security personnel.
Study: NCT03354065

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TIME OF FEEDING
Description: Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TIME OF FEEDING
Description: Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)
Study: NCT02988115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bempedoic acid
Description: bempedoic acid 180 mg tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo tablet
Study: NCT04486586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS plus Speech-Language Therapy
Description: Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm\^2; estimated total charge 0.048 C/cm\^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active tDCS plus Speech-Language Therapy
Description: Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm\^2; estimated total charge 0.048 C/cm\^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham plus Speech-Language Therapy
Description: Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham plus Speech-Language Therapy
Description: Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).
Study: NCT02861521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoe lift
Description: Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham shoe modification
Study: NCT02710825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathy
Description: The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: superficial palpatory agreement
Description: The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
Study: NCT02990273

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Study: NCT03170960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
Study: NCT04064047

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Trans rectal ultrasound guided prostate biopsy
Description: The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound guided prostate biopsy
Description: The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound guided prostate biopsy
Description: The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
Study: NCT02588963

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
Study: NCT00074932

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Myozyme
Description: 20 mg/kg
Study: NCT02771561

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Patent Foramen Ovale Closure
Description: Transoesophageal guided percutaneous patent foramen ovale closure using Gore™ septal occluder device
Study: NCT01558765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation
Description: Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).